干扰素α-2b生物类似药(Probiomed SA de CV)(Interferon alfa-2b biosimilar(Probiomed SA de CV)) - 药物靶点：IFNAR_在研适应症：尖锐湿疣，毛细胞白血病，乙型肝炎_专利_临床

概要

基本信息

药物类型

干扰素、生物类似药

别名

Urifron

靶点

IFNAR

作用机制

IFNAR激动剂(干扰素α/β受体复合体激动剂)、免疫刺激剂、先天性抗病毒免疫应答诱导剂

治疗领域

肿瘤免疫系统疾病感染+ [6]

在研适应症

尖锐湿疣毛细胞白血病乙型肝炎+ [4]

非在研适应症-

原研机构

Probiomed SA de CV

在研机构

Probiomed SA de CV

非在研机构-

最高研发阶段批准上市

首次获批日期

墨西哥 (2006-03-01),

尖锐湿疣毛细胞白血病乙型肝炎+ [4]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 26333714

当前序列信息引自: *****

关联

7

项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的临床试验

NCT04093323

/ Recruiting临床2期IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-13

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT04379518

/ Suspended临床1/2期IIT

Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

开始日期2020-11-17

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT03899987

/ Suspended临床2期IIT

Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen

This phase II trial studies how well aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.

开始日期2019-11-29

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的临床结果

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的转化医学

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的专利（医药）

登录后查看更多信息

100 项与干扰素α-2b生物类似药(Probiomed SA de CV) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
尖锐湿疣	墨西哥	Probiomed SA de CV	2006-03-01
毛细胞白血病	墨西哥	Probiomed SA de CV	2006-03-01
乙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
丙型肝炎	墨西哥	Probiomed SA de CV	2006-03-01
卡波西肉瘤	墨西哥	Probiomed SA de CV	2006-03-01
黑色素瘤	墨西哥	Probiomed SA de CV	2006-03-01
多发性骨髓瘤	墨西哥	Probiomed SA de CV	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03403634 (CTgov)	临床2期	肝转移 \| 复发性结直肠癌 \| 结直肠癌	19	Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib	夢構廠鏇壓築襯襯鏇獵(鏇壓齋餘積膚糧構鬱積) = 簾醖範積選網鹹網襯憲製襯廠選鏇鏇餘蓋繭鑰 (鹽觸顧襯製遞簾膚糧憲, 網醖糧壓築獵齋鬱膚壓 ~ 顧廠艱壓選鏇膚願鹹醖) 更多	-	2022-03-02
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sorafenib Tosylate (Sorafenib Tosylate)	壓膚簾窪衊餘構糧簾顧(壓憲衊築鬱遞鹽餘廠齋) = 遞醖範獵簾顧窪選齋願網築範蓋鬱夢餘簾鏇淵 (鹹廠壓鑰糧鹹憲襯鹹襯, 願鹽餘衊鑰艱鑰蓋繭醖 ~ 鏇鹹廠遞遞築製衊簾壓) 更多	-	2016-09-16
NCT00126594 (CTgov)	临床2期	转移性肾细胞癌	80	Laboratory Biomarker Analysis+Sch 30500+Heberon Alfa+Urifron+Sorafenib Tosylate (Sorafenib Tosylate, Recombinant Interferon Alfa-2b)	壓膚簾窪衊餘構糧簾顧(壓憲衊築鬱遞鹽餘廠齋) = 淵艱顧積夢齋顧獵願簾網築範蓋鬱夢餘簾鏇淵 (鹹廠壓鑰糧鹹憲襯鹹襯, 觸顧齋獵壓夢築餘鏇選 ~ 鬱顧衊製簾膚遞糧蓋簾) 更多	-	2016-09-16